Streetbeat News

PTPI

Petros Pharmaceuticals, Inc.

https://www.petrospharma.com

Industry

Drug Manufacturers - Specialty & Generic

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.

Open

0.26

Mkt cap

2.7M

Volume

396K

High

0.28

P/E Ratio

-0.07

52-wk high

2.27

Low

0.25

Div yield

N/A

52-wk low

0.22

The article highlights significant intraday movements in health care stocks on Friday. Iterum Therapeutics, ImmunityBio, Impact BioMedical, Nexalin Technology, 180 Life Sciences, and Petros Pharma saw notable gains, while Monopar Therapeutics, Bionomics, Catheter Precision, Tyra Biosciences, Zenas BioPharma, and NewGenIvf Group experienced declines.

Portfolio Pulse from Benzinga Insights

October 25, 2024 | 4:31 pm

Several healthcare stocks experienced significant price movements in Wednesday's after-market session. CNS Pharma, DBV Technologies, and Molina Healthcare were among the gainers, while Enveric Biosciences and Evotec saw declines. Molina Healthcare's rise is linked to its Q3 earnings release.

Portfolio Pulse from Benzinga Insights

October 23, 2024 | 8:31 pm

In Tuesday's after-market session, several health care stocks experienced significant price movements. Biodexa Pharmaceuticals saw a remarkable 119% increase, while Petros Pharma, Helius Medical Tech, Vaccinex, Aditxt, and Gain Therapeutics also posted gains. Conversely, NewGenIvf Group, HCW Biologics, Carmell, ABVC BioPharma, Tevogen Bio Holdings, and Lipella Pharmaceuticals experienced declines.

Portfolio Pulse from Benzinga Insights

October 15, 2024 | 8:30 pm

Petros Pharmaceuticals (NASDAQ: PTPI) aims to transition its prescription erectile dysfunction (ED) therapy, Stendra (avanafil), to over-the-counter (OTC) status. This move could significantly expand the ED market, potentially tripling its size. The company is leveraging its expertise in the Rx-to-OTC switch market and has aligned with the FDA for a pivotal study review in 2H 2024.

Portfolio Pulse from Vandana Singh

June 17, 2024 | 7:08 am

Signet Jewelers Limited (NYSE:SIG) shares fell over 12% due to mixed first-quarter earnings, including a significant drop in same-store sales. The company reported a 9.5% year-on-year sales decline, missing analyst estimates, but beat EPS expectations. Other stocks mentioned include BioRestorative Therapies, Zapp Electric Vehicles, Sharps Technology, and Broadcom, among others, with various gains and losses based on recent announcements and earnings reports.

Portfolio Pulse from Avi Kapoor

June 13, 2024 | 6:07 pm

The article highlights significant intraday movements in healthcare stocks on Thursday. Longeveron, BioRestorative Therapies, Aethlon Medical, Sharps Technology, Biomea Fusion, and iSpecimen saw notable gains, while Assure Holdings, CERo Therapeutics Holdings, Cara Therapeutics, Kronos Bio, Cyclerion Therapeutics, and Petros Pharma experienced declines.

Portfolio Pulse from Benzinga Insights

June 13, 2024 | 4:31 pm

Broadcom Inc. (NASDAQ:AVGO) shares surged 13.5% in pre-market trading after posting strong Q2 results, declaring a $5.25 quarterly dividend, and announcing a 10-for-1 stock split. The company also raised its FY 2024 revenue guidance to $51 billion. Other notable pre-market movers include Neo-Concept International Group Holdings Limited (NASDAQ:NCI), Fangdd Network Group Ltd. (NASDAQ:DUO), and Grupo Supervielle S.A. (NYSE:SUPV) among gainers, and Assure Holdings Corp. (NASDAQ:IONM) and DDC Enterprise Limited (NYSE:DDC) among losers.

Portfolio Pulse from Avi Kapoor

June 13, 2024 | 12:16 pm

The article highlights the pre-market movements of 12 health care stocks on Thursday. Significant gainers include Longeveron (LGVN), JanOne (JAN), Bionomics (BNOX), BioRestorative Therapies (BRTX), Holdco Nuvo Group DG (NUVO), and Vivani Medical (VANI). Notable losers are Assure Holdings (IONM), Cara Therapeutics (CARA), Apyx Medical (APYX), Petros Pharma (PTPI), Catheter Precision (VTAK), and Connect Biopharma Holdings (CNTB).

Portfolio Pulse from Benzinga Insights

June 13, 2024 | 12:07 pm

The article highlights the performance of various health care stocks during Wednesday's after-market session. Notable gainers include OneMedNet (ONMD), Kintara Therapeutics (KTRA), and Galera Therapeutics (GRTX), while significant losers include Onconetix (ONCO), Agilent Technologies (A), and Immunovant (IMVT).

Portfolio Pulse from Benzinga Insights

May 29, 2024 | 8:31 pm

Petros Pharmaceuticals (NASDAQ:PTPI) has formed an Advisory Committee to guide the potential Rx-to-OTC switch for STENDRA, focusing on development and communication with the U.S. FDA.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 1:54 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.